ART-501 Shows Promise in Phase 2a Trial for Autism Spectrum Disorder Treatment
核心洞察
Artisan Therapeutics (搜索) and Tulex Pharmaceuticals (搜索) reported positive Phase 2a results for ART-501 (搜索), with four out of six participants showing meaningful clinical benefit in autism spectrum disorder treatment.
The novel oral liquid extended-release formulation demonstrated behavioral improvements across multiple domains including irritability, social withdrawal, stereotypic behaviors, and hyperactivity compared to baseline.
ART-501 (搜索) was generally well-tolerated with mostly mild and transient adverse events and no serious adverse events observed in the pilot study.
Artisan Therapeutics (搜索) and Tulex Pharmaceuticals (搜索) announced encouraging Phase 2a clinical results for ART-501 (搜索), a novel oral liquid extended-release formulation targeting autism spectrum disorder (ASD)-related conditions. The pilot proof-of-concept study demonstrated meaningful signs of clinical benefit in four out of six participants, with the treatment showing a favorable safety profile.
Clinical Efficacy Results
Behavioral improvements were observed in the majority of participants as measured by the Aberrant Behavior Checklist – Second Edition (ABC-2). Notable reductions were seen across multiple ABC-2 subscales during low-dose ART-501 (搜索) dosing compared to baseline, including:
- Irritability
- Lethargy/social withdrawal
- Stereotypic behaviors
- Hyperactivity/non-compliance
The ABC-2 irritability subscale represents an established clinical measure that has served as a primary endpoint in FDA-approved therapies for irritability associated with ASD.
Study Design and Safety Profile
The multicenter trial was conducted at two U.S. clinical sites, enrolling six adult participants with diagnostically confirmed ASD, with five completing treatment. The study design included baseline assessments followed by an open-label period with low-dose ART-501 (搜索), then a blinded, placebo-controlled, crossover period involving higher-dose ART-501.
ART-501 (搜索) demonstrated a favorable safety profile, with adverse events reported as mostly mild and transient. No serious adverse events were observed during the study period.
Expert Commentary
Dr. Ann Childress, M.D., an investigator in the trial, emphasized the clinical significance of the findings: "Autism presents significant challenges for patients and their families, including repetitive behaviors, communication difficulties, and impaired social interactions. It was very encouraging to see signals of efficacy in several of the participants in the ART-501 (搜索) study, which supports continued exploration of this use of ART-501 in a larger Phase 2/3 study."
Dr. Colleen Craig, M.D., Interim Chief Medical Officer at Artisan Therapeutics (搜索), stated: "We are deeply encouraged by the early signs of clinical benefit observed in this Phase 2a study of ART-501 (搜索). These results highlight the therapeutic potential of our novel extended-release formulation in addressing core symptoms of ASD. At Artisan, our mission is to pursue science-driven innovation for underserved neurodevelopmental conditions, and this milestone represents an important step forward."
Drug Development and Next Steps
ART-501 (搜索), formerly known as ARD-501 or TLX-032, is a proprietary oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug developed through a joint venture between Tulex and Artisan. The companies plan to advance ART-501 into further clinical development based on these positive results.
The development represents a collaborative effort between Artisan Therapeutics (搜索), a wholly owned subsidiary of Aardvark Therapeutics focused on ART-501 (搜索) development, and Tulex Pharmaceuticals (搜索), a U.S.-based company specializing in NDA and ANDA products of existing molecules in new dosage forms or administration routes.